Untargeted sequencing of circulating microRNAs in a healthy and diseased older population
Lukas Streese, Philippe Demougin, Paula Iborra, Alexander Kanitz, Arne Deiseroth, Julia M Kröpfl, Arno Schmidt-Trucksäss, Mihaela Zavolan, Henner Hanssen, Lukas Streese, Philippe Demougin, Paula Iborra, Alexander Kanitz, Arne Deiseroth, Julia M Kröpfl, Arno Schmidt-Trucksäss, Mihaela Zavolan, Henner Hanssen
Abstract
We performed untargeted profiling of circulating microRNAs (miRNAs) in a well characterized cohort of older adults to verify associations of health and disease-related biomarkers with systemic miRNA expression. Differential expression analysis revealed 30 miRNAs that significantly differed between healthy active, healthy sedentary and sedentary cardiovascular risk patients. Increased expression of miRNAs miR-193b-5p, miR-122-5p, miR-885-3p, miR-193a-5p, miR-34a-5p, miR-505-3p, miR-194-5p, miR-27b-3p, miR-885-5p, miR-23b-5b, miR-365a-3p, miR-365b-3p, miR-22-5p was associated with a higher metabolic risk profile, unfavourable macro- and microvascular health, lower physical activity (PA) as well as cardiorespiratory fitness (CRF) levels. Increased expression of miR-342-3p, miR-1-3p, miR-92b-5p, miR-454-3p, miR-190a-5p and miR-375-3p was associated with a lower metabolic risk profile, favourable macro- and microvascular health as well as higher PA and CRF. Of note, the first two principal components explained as much as 20% and 11% of the data variance. miRNAs and their potential target genes appear to mediate disease- and health-related physiological and pathophysiological adaptations that need to be validated and supported by further downstream analysis in future studies.Clinical Trial Registration: ClinicalTrials.gov: NCT02796976 ( https://ichgcp.net/clinical-trials-registry/NCT02796976 ).
Conflict of interest statement
The authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
- Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ. Res. 2016;118:703–720.
- de Gonzalo-Calvo D, et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: A novel tool for personalized medicine? Eur. Heart J. 2019;40:1643–1650.
- Navickas R, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc. Res. 2016;111:322–337.
- Karakas M, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur. Heart J. 2017;38:516–523.
- De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs. Circulation. 2011;124:1936–1944.
- De Rosa S, et al. Transcoronary concentration gradients of circulating microRNAs in heart failure. Eur. J. Heart Fail. 2018;20:1000–1010.
- Wang GK, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 2010;31:659–666.
- Hoefer IE, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur. Heart J. 2015;36:2635–2642.
- Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler. Thromb. Vasc. Biol. 2011;31:2383–2390.
- Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 2008;15:261–271.
- Fish JE, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell. 2008;15:272–284.
- Schober A, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 2014;20:368–376.
- Fichtlscherer S, et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010;107:677–684.
- Zampetaki A, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010;107:810–817.
- Bao F, Slusher AL, Whitehurst M, Huang CJ. Circulating microRNAs are upregulated following acute aerobic exercise in obese individuals. Physiol. Behav. 2018;197:15–21.
- Xu T, et al. Circulating microRNAs in response to exercise. Scand. J. Med. Sci. Sports. 2015;25:e149–e154.
- Zhou QL, et al. Circulating microRNAs in response to exercise training in healthy adults. Front. Genet. 2020 doi: 10.3389/fgene.2020.00256.
- Streese L, et al. Physical activity may drive healthy microvascular ageing via downregulation of p66(Shc) Eur. J. Prev. Cardiol. 2020;27:168–176.
- Zierath JR, Wallberg-Henriksson H. Looking ahead perspective: Where will the future of exercise biology take us? Cell Metab. 2015;22:25–30.
- Streese L, Deiseroth A, Schafer J, Schmidt-Trucksass A, Hanssen H. Exercise, arterial crosstalk-modulation, and inflammation in an aging population: The ExAMIN AGE study. Front. Physiol. 2018 doi: 10.3389/fphys.2018.00116.
- World-Medical-Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
- Berninger P, Gaidatzis D, van Nimwegen E, Zavolan M. Computational analysis of small RNA cloning data. Methods. 2008;44:13–21.
- Hoffmann S, et al. Fast Mapping of Short Sequences with Mismatches, Insertions and Deletions Using Index Structures. Plos Comput. Biol. 2009;5:e1000502.
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.
- Gumienny R, Zavolan M. Accurate transcriptome-wide prediction of microRNA targets and small interfering RNA off-targets with MIRZA-G. Nucleic Acids Res. 2015;43:9095.
- Hou Z, et al. Longterm exercise-derived exosomal miR-342-5p: A novel exerkine for cardioprotection. Circ. Res. 2019;124:1386–1400.
- Lu H, et al. Elevated circulating stearic acid leads to a major lipotoxic effect on mouse pancreatic beta cells in hyperlipidaemia via a miR-34a-5p-mediated PERK/p53-dependent pathway. Diabetologia. 2016;59:1247–1257.
- Liu CH, et al. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2018;69:1335–1348.
- Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease? Eur. Heart J. 2016;37:3260–3266.
- Yu J, et al. MiR-27b-3p inhibition enhances browning of epididymal fat in high-fat diet induced obese mice. Front. Endocrinol. (Lausanne) 2019;10:38.
- Arias N, et al. MicroRNAs involved in the browning process of adipocytes. J. Physiol. Biochem. 2016;72:509–521.
- Gui JH, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. 2011;120:183–193.
- Raitoharju E, et al. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci. Rep. 2016;6:38262.
- Liang TY, Lou JY. Increased expression of mir-34a-5p and clinical association in acute ischemic stroke patients and in a rat model. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016;22:2950–2955.
- Chua CEL, Tang BL. miR-34a in neurophysiology and neuropathology. J. Mol. Neurosci. 2019;67:235–246.
- Wang Y, et al. Circulating miR-22-5p and miR-122-5p are promising novel biomarkers for diagnosis of acute myocardial infarction. J. Cell. Physiol. 2019;234:4778–4786.
- Zhang X, Gu H, Wang L, Huang F, Cai J. MiR-885-3p is down-regulated in peripheral blood mononuclear cells from T1D patients and regulates the inflammatory response via targeting TLR4/NF-kappaB signaling. J. Gene Med. 2020;22:e3145.
- Escate R, Mata P, Cepeda JM, Padreo T, Badimon L. miR-505-3p controls chemokine receptor up-regulation in macrophages: Role in familial hypercholesterolemia. FASEB J. 2018;32:601–612.
- Chen Z, et al. Inflammation-dependent downregulation of miR-194-5p contributes to human intervertebral disc degeneration by targeting CUL4A and CUL4B. J. Cell Physiol. 2019;234:19977–19989.
- Boureima Oumarou D, et al. Involvement of microRNA-23b-5p in the promotion of cardiac hypertrophy and dysfunction via the HMGB2 signaling pathway. Biomed. Pharmacother. 2019;116:108977.
- Qu Y, Zhang N. miR-365b-3p inhibits the cell proliferation and migration of human coronary artery smooth muscle cells by directly targeting ADAMTS1 in coronary atherosclerosis. Exp. Ther. Med. 2018;16:4239–4245.
- Khalyfa A, Kheirandish-Gozal L, Bhattacharjee R, Khalyfa AA, Gozal D. Circulating microRNAs as potential biomarkers of endothelial dysfunction in obese children. Chest. 2016;149:786–800.
- Li TR, et al. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin. Chim. Acta. 2011;412:66–70.
- Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 2007;101:59–68.
- Yang Q, et al. MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation. Int. J. Cardiol. 2014;177:925–934.
- Lee IM, et al. Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy. Lancet. 2012;380:219–229.
- Dufresne S, Rebillard A, Muti P, Friedenreich CM, Brenner DR. A review of physical activity and circulating miRNA expression: Implications in cancer risk and progression. Cancer Epidemiol. Biomark. Prev. 2018;27:11–24.
- Ray SL, et al. The role of miR-342 in vascular health. Study in subclinical cardiovascular disease in mononuclear cells, plasma, inflammatory cytokines and PANX2. Int. J. Mol. Sci. 2020;21:7217.
- Ai J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010;391:73–77.
- Kuwabara Y, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011;4:446–454.
- Wu T, et al. Serum exosomal MiR-92b-5p as a potential biomarker for acute heart failure caused by dilated cardiomyopathy. Cell Physiol. Biochem. 2018;46:1939–1950.
- Wu T, et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure. J. Thorac. Dis. 2018;10:6211.
- Poy MN, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–230.
- Sen S, et al. Myotrophin—Purification of a novel peptide from spontaneously hypertensive rat-heart that influences myocardial growth. J. Biol. Chem. 1990;265:16635–16643.
- Das B, et al. Nuclear co-translocation of myotrophin and p65 stimulates myocyte growth—Regulation by myotrophin hairpin loops. J. Biol. Chem. 2008;283:27947–27956.
- Das B, et al. Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc. Res. 2010;87:524–534.
- Huttlin EL, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545:505–509.
- Szklarczyk D, et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–D613.
- Zhang GH, et al. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br. J. Cancer. 2019;121:1069–1078.
- Liu L, et al. Endothelial forkhead box transcription factor P1 regulates pathological cardiac remodeling through transforming growth factor-beta 1-endothelin-1 signal pathway. Circulation. 2019;140:665–680.
- Dressel U, et al. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J. Biol. Chem. 2001;276:17007–17013.
Source: PubMed